title: Megavoltage pituitary irradiation in the management of Cushing's disease and Nelson's syndrome: long-term follow-up.
abstract: We report the long-term follow-up of the clinical and biochemical effects of megavoltage pituitary irradiation (radiotherapy; RT), administered as primary or secondary therapy, for pituitary Cushing's disease and Nelson's syndrome in 52 patients. Irradiation was administered, from a 4-15 MeV linear accelerator, via a three-field technique (two lateral, one frontal), to a total dose of 4500 cGy (rad) in 25 fractions over 35 days. Twenty-one patients received RT as primary ablative therapy for Cushing's disease and were under follow-up 5.8 to 15.5 years later (median 9.5 years). All were initially treated with metyrapone to induce normal mean plasma cortisol levels, and all achieved clinical remission on this therapy. At latest follow-up, 12 (57%) are off all therapy, in clinical remission, with a normal mean cortisol through the day; however, only two show completely normal plasma cortisol responses to dynamic testing; four remain on medical therapy with metyrapone or op'DDD and all have required a steady dose reduction accompanied by falling plasma ACTH levels; five have required alternative therapy with bilateral adrenalectomy and/or transsphenoidal hypophysectomy. Fifteen patients received RT for Nelson's syndrome, developing after bilateral adrenalectomy, and have been followed up for 1.5 to 17.3 years (median 9.6 years). Fourteen patients showed progressive depigmentation, shrinkage of the pituitary adenoma and fall in plasma ACTH levels to 1-72% (median 16%) of the pre-RT basal value. In the remaining patient an initial fall in plasma ACTH was followed by tumour enlargement at 6 years, leading to death at 11 years after RT. Of the remaining patients, results are assessed in nine who received RT after unsuccessful transsphenoidal surgery, three after transfrontal surgery for aggressive macroadenomas, and four prophylactically after bilateral adrenalectomy. Radiotherapy remains a valuable second-line therapy for Cushing's disease and its complications.
authors.affiliation: Department of Endocrinology, St Bartholomew's Hospital, London, UK.
authors.forename: T A
authors.initials: TA
authors.lastname: Howlett
authors.forename: P N
authors.initials: PN
authors.lastname: Plowman
authors.forename: J A
authors.initials: JA
authors.lastname: Wass
authors.forename: L H
authors.initials: LH
authors.lastname: Rees
authors.forename: A E
authors.initials: AE
authors.lastname: Jones
authors.forename: G M
authors.initials: GM
authors.lastname: Besser
mesh_terms: D000293:Adolescent; D000324:Adrenocorticotropic Hormone / Q000032:analysis; D000328:Adult; D000368:Aged; D003480:Cushing Syndrome / Q000532:radiotherapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008297:Male; D008797:Metyrapone / Q000494:pharmacology; D008875:Middle Aged; D009347:Nelson Syndrome / Q000532:radiotherapy*; D010902:Pituitary Gland / Q000000981:diagnostic imaging*; D010911:Pituitary Neoplasms / Q000532:radiotherapy*; D011859:Radiography; D011882:Radiotherapy, High-Energy
chemical_list: D000324:Adrenocorticotropic Hormone; D006854:Hydrocortisone; D008797:Metyrapone